New drug combo aims to tame stem cell transplant complications
NCT ID NCT05120570
First seen Jan 06, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study tested whether adding an experimental drug (VIC-1911) to standard medications can prevent graft-versus-host disease (GVHD) and cancer relapse after a stem cell transplant. Sixteen adults with blood cancers like leukemia or lymphoma took part. The goal was to find the best dose of VIC-1911 that safely reduces harmful immune reactions while keeping the transplant effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.